ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - ceftazidime pentahydrate, quantity: 1164.8 mg (equivalent: ceftazidime, qty 1000 mg) - injection, powder for - excipient ingredients: sodium carbonate - treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not to ceftazidime; as an alternative to aminoglycosides in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other antipseudomonal antibiotics cannot be used. indications include the folowing: severe infections in general (e.g. septicaemia including neonatal sepsis, bacteraemia; in patients in intensive care units with specific problems, e.g. infected burns). respiratory tract (e.g. pneumonia, bronchopneumonia, infected pleurisy, infected bronchiectasis and bronchitis). severe ear, nose and throat infections (e.g. otitis media, mastoiditis). urinary tract (e.g. acute and chronic pyelonephritis, pyelitis, cystitis - bacterial only; infections associated with bladder and renal stones). skin and soft tissue (e.g. erysipelas abscesses, cellulitis, infected burns and wounds, mastitis). gastrointestinal and abdominal (e.g. intra-abdominal abscesses, enterocolitis). bone and joint (e.g. osteitis, osteomyelitis, septic arthritis, infected burstis).

इसराइल - अंग्रेज़ी - Ministry of Health

abic marketing ltd, israel - ceftazidime as pentahydrate - powder for solution for injection - ceftazidime as pentahydrate 1 g/vial - ceftazidime - ceftazidime - treatment of single or multiple infections caused by susceptible microorganisms.

आयरलैंड - अंग्रेज़ी - HPRA (Health Products Regulatory Authority)

hospira uk limited - ceftazidime pentahydrate - pdr for soln for injection - 500 milligram - other beta-lactam antibacterials

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

b. braun medical inc. - ceftazidime (unii: 9m416z9qnr) (ceftazidime anhydrous - unii:dzr1ent301) - ceftazidime anhydrous 1 g in 50 ml - ceftazidime for injection and dextrose injection is indicated for the treatment of lower respiratory tract infections, including pneumonia, caused by pseudomonas aeruginosa and other pseudomonas spp.; haemophilus influenzae , including ampicillin-resistant isolates; klebsiella spp.; enterobacter spp.; proteus mirabilis ; escherichia coli ; serratia spp.; citrobacter spp.; streptococcus pneumoniae ; and staphylococcus aureus (methicillin-susceptible isolates). ceftazidime for injection and dextrose injection is indicated for the treatment of skin and skin-­structure infections caused by pseudomonas aeruginosa ; klebsiella spp.; escherichia coli ; proteus spp., including proteus mirabilis and indole-positive proteus ; enterobacter spp.; serratia spp.; staphylococcus aureus (methicillin-susceptible isolates); and streptococcus pyogenes (group a beta-hemolytic streptococci). ceftazidime for injection and dextrose injection is indicated for the treatment of bacterial septicemia caused by pseudomonas

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

sandoz inc - ceftazidime (unii: 9m416z9qnr) (ceftazidime anhydrous - unii:dzr1ent301) - ceftazidime for injection, usp is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: ceftazidime for injection, usp may be used alone in cases of confirmed or suspected sepsis. ceftazidime has been used successfully in clinical trials as empiric therapy in cases where various concomitant therapies with other antibiotics have been used. ceftazidime for injection, usp may also be used concomitantly with other antibiotics, such as aminoglycosides, vancomycin, and clindamycin; in severe and life-threatening infections; and in the immunocompromised patient. when such concomitant treatment is appropriate, prescribing information in the labeling for the other antibiotics should be followed. the dose depends on the severity of the infection and the patient’s condition. to reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftazidime for injection, usp and other antibacterial drugs, ceftazidime f

इसराइल - अंग्रेज़ी - Ministry of Health

vitamed pharmaceutical industries ltd - ceftazidime as pentahydrate - powder for solution for injection - ceftazidime as pentahydrate 1.000 g/vial - ceftazidime - ceftazidime-vit is indicated for the treatment of the infections listed below in adults and children including neonates (from birth).• nosocomial pneumonia• broncho-pulmonary infections in cystic fibrosis• bacterial meningitis• chronic suppurative otitis media• malignant otitis externa• complicated urinary tract infections• complicated skin and soft tissue infections• complicated intra-abdominal infections• bone and joint infections• peritonitis associated with dialysis in patient on capd.treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.ceftazidime may be used in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection.ceftazidime may be used in the peri-operative prophylaxis of urinary tract infections for patients undergoing trans-urethral resection of the prostate (turp).the selection of ceftazidime should take into account its antibacterial spectrum, which is mainly restricted to aerobic gram negative bacteria.ceftazidime should be co-administered with other antibacterial agents whenever the possible range of causive bacteria would not fall within its spectrum of activity.consideration should be given to official guidelines on the appropriate use of antibacterial agents.

तंज़ानिया - अंग्रेज़ी - Tanzania Medicinces & Medical Devices Authority

b&o pharm, france - ceftazidime pentahydrate - powder and solvent for solution for injection - 1

यूनाइटेड किंगडम - अंग्रेज़ी - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - ceftazidime pentahydrate; avibactam sodium - powder for solution for infusion - 2gram ; 500mg

आर्मेनिया - अंग्रेज़ी - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

glaxosmithkline manufacturing spa - ceftazidime (ceftazidime pentahydrate), avibactam (avibactam sodium) - powder for solution for infusion - 2g+ 0.5g

आर्मेनिया - अंग्रेज़ी - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

acs dobfar spa - ceftazidime (ceftazidime pentahydrate), avibactam (avibactam sodium) - powder for solution for infusion - 2g+ 0.5g